Kitov Pharma is a development-stage pharmaceutical company focused on two operating segments: Oncology, which includes NT219, a therapeutic candidate which is a small molecule that targetst wo signal transduction pathways which are involved in the development of cancer drugresistance mechanisms, and which is in the late pre-clinical stage of development; and Painand Hypertension, which includes Consensi™, a combination drug approved by the United States Food and Drug Administration for the simultaneous treatmentof two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existingor caused by the treatment for osteoarthritis. We show 1 historical shares outstanding datapoints in our coverage of KTOV's shares outstanding history.
Understanding the changing numbers of KTOV shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like KTOV versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching KTOV by allowing them to research KTOV shares outstanding history
as well as any other stock in our coverage universe. |
Free KTOV Email Alerts:
Video: Shares Outstanding Importance
